TWI629283B - 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱 - Google Patents

來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱 Download PDF

Info

Publication number
TWI629283B
TWI629283B TW102106384A TW102106384A TWI629283B TW I629283 B TWI629283 B TW I629283B TW 102106384 A TW102106384 A TW 102106384A TW 102106384 A TW102106384 A TW 102106384A TW I629283 B TWI629283 B TW I629283B
Authority
TW
Taiwan
Prior art keywords
suspension
precipitate
immunoglobulin
cohen
igg
Prior art date
Application number
TW102106384A
Other languages
English (en)
Chinese (zh)
Other versions
TW201348248A (zh
Inventor
里奧波 布魯克史維格
湯瑪士 根帝格
茱利亞 紐柏格
沃夫剛 泰許那
漢斯 彼得 史瓦茲
Original Assignee
巴克斯歐塔公司
巴克斯歐塔有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47833446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI629283(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 巴克斯歐塔公司, 巴克斯歐塔有限公司 filed Critical 巴克斯歐塔公司
Publication of TW201348248A publication Critical patent/TW201348248A/zh
Application granted granted Critical
Publication of TWI629283B publication Critical patent/TWI629283B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW102106384A 2012-02-23 2013-02-23 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱 TWI629283B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261602488P 2012-02-23 2012-02-23
US61/602,488 2012-02-23

Publications (2)

Publication Number Publication Date
TW201348248A TW201348248A (zh) 2013-12-01
TWI629283B true TWI629283B (zh) 2018-07-11

Family

ID=47833446

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102106384A TWI629283B (zh) 2012-02-23 2013-02-23 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱

Country Status (25)

Country Link
US (1) US9782477B2 (enExample)
EP (2) EP4119574A1 (enExample)
JP (1) JP6291423B2 (enExample)
KR (1) KR101930582B1 (enExample)
CN (1) CN104245730B (enExample)
AR (1) AR090425A1 (enExample)
AU (1) AU2013203112B2 (enExample)
BR (1) BR112014020602B1 (enExample)
CA (1) CA2864715A1 (enExample)
CL (1) CL2014002225A1 (enExample)
CO (1) CO7081143A2 (enExample)
DK (1) DK2817334T3 (enExample)
EA (1) EA032478B1 (enExample)
ES (1) ES2928954T3 (enExample)
HU (1) HUE060195T2 (enExample)
IL (1) IL234103B (enExample)
MX (2) MX365236B (enExample)
MY (1) MY167235A (enExample)
NZ (1) NZ628529A (enExample)
PL (1) PL2817334T3 (enExample)
PT (1) PT2817334T (enExample)
SG (1) SG11201405149UA (enExample)
SI (1) SI2817334T1 (enExample)
TW (1) TWI629283B (enExample)
WO (1) WO2013126904A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CN104004090A (zh) * 2014-06-12 2014-08-27 新疆德源生物工程有限公司 一种人免疫球蛋白的制备方法
CN104004091B (zh) * 2014-06-12 2016-08-17 新疆德源生物工程有限公司 一种人免疫球蛋白的制备工艺
GB201413227D0 (en) 2014-07-25 2014-09-10 Bioproducts Lab Ltd Process
ES2887588T3 (es) * 2015-08-13 2021-12-23 Kamada Ltd Composiciones derivadas de pasta de fracción de Cohn y uso de las mismas
US11040068B2 (en) * 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
IL278584B2 (en) * 2018-05-17 2025-08-01 Csl Behring Ag Method and system of protein extraction
CA3157446A1 (en) 2019-11-20 2021-05-27 Csl Behring Ag Method for extracting a protein from a precipitate and method for precipitating impurities
EP4118108A4 (en) * 2020-04-10 2024-05-15 Plasma Technologies, LLC COMPOSITIONS AND METHODS FOR HIGHLY EFFICIENT SIMPLIFIED PROTEIN ISOLATION
EP4240757A2 (en) * 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
CN112250757A (zh) * 2020-11-13 2021-01-22 广东深蓝生物科技有限公司 一种猪血浆中蛋白质的提取纯化方法
JP2024501025A (ja) * 2020-12-28 2024-01-10 プラズマ テクノロジーズ エルエルシー 免疫グロブリンｇのプロセススケールでの単離のためのシステム及び方法
CN118580342B (zh) * 2024-05-20 2025-02-07 广东丹霞生物制药有限公司 一种静脉注射用人免疫球蛋白制剂的制备工艺

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476109A (en) * 1981-09-29 1984-10-09 Fujirebio Kabushiki Kaisha Method of preparing gamma globulin suitable for intravenous administration
WO2003004982A1 (en) * 2001-07-05 2003-01-16 Hamamatsu Photonics K.K. Spectroscopic device

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (enExample) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US3998946A (en) 1975-04-23 1976-12-21 The Regents Of The University Of Minnesota Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same
US4136094A (en) 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
US6284874B1 (en) 1994-06-17 2001-09-04 Alpha Therapeutic Corporation Process for separating α1-proteinase inhibitor from cohn fraction IV1 and IV4 paste
US5616693A (en) 1996-07-01 1997-04-01 Alpha Therapeutic Corporation Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
CA2232420A1 (en) 1997-03-19 1998-09-19 The Green Cross Corporation Immunoglobulin preparation and preparation process thereof
GB9705810D0 (en) * 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
CA2251342A1 (en) 1997-10-23 1999-04-23 Yutaka Hirao Room temperature storable immunoglobulin preparation for intravenous injection
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
US6893639B2 (en) * 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
DK1664123T4 (da) 2003-09-22 2012-03-05 Kamada Ltd Storskalafremstilling af alfa-1-proteinaseinhibitor og anvendelse deraf
US20070244305A1 (en) 2004-01-30 2007-10-18 Suomen Punainen Risti Veripalvelu Process for The Manufacture of Virus Safe Immunoglobulin
CA2557229C (en) 2004-02-27 2012-07-10 Octapharma Ag A method of providing a purified, virus safe antibody preparation
US7807435B2 (en) 2005-08-11 2010-10-05 Baxter International Inc. Method for the purification of alpha-1 proteinase inhibitor (a1PI)
ES2595059T3 (es) 2007-03-20 2016-12-27 Csl Behring Gmbh Métodos para la producción a escala industrial de preparados terapéuticos del Factor H del complemento a partir de plasma humano
US8546548B2 (en) 2009-05-27 2013-10-01 Baxter International Inc. Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
WO2011011753A1 (en) 2009-07-23 2011-01-27 Baxter International Inc. Manufacture of factor h (fh) and fh-derivatives from plasma
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) * 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
EP2596014B1 (en) 2010-07-23 2018-11-28 Baxalta GmbH Manufacture of inter-alpha-inhibitor proteins (iaip) from plasma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476109A (en) * 1981-09-29 1984-10-09 Fujirebio Kabushiki Kaisha Method of preparing gamma globulin suitable for intravenous administration
WO2003004982A1 (en) * 2001-07-05 2003-01-16 Hamamatsu Photonics K.K. Spectroscopic device

Also Published As

Publication number Publication date
IL234103B (en) 2019-11-28
CA2864715A1 (en) 2013-08-29
HUE060195T2 (hu) 2023-02-28
BR112014020602B1 (pt) 2022-12-20
PL2817334T3 (pl) 2022-11-21
SG11201405149UA (en) 2014-09-26
IL234103A0 (en) 2014-09-30
EP2817334A1 (en) 2014-12-31
ES2928954T3 (es) 2022-11-23
TW201348248A (zh) 2013-12-01
CN104245730B (zh) 2017-09-01
BR112014020602A2 (pt) 2018-09-11
MY167235A (en) 2018-08-14
EP4119574A1 (en) 2023-01-18
AR090425A1 (es) 2014-11-12
CO7081143A2 (es) 2014-10-10
KR101930582B1 (ko) 2018-12-18
MX365236B (es) 2019-05-28
JP2015509506A (ja) 2015-03-30
PT2817334T (pt) 2022-10-17
CL2014002225A1 (es) 2015-01-16
EP2817334B1 (en) 2022-09-21
MX2019005999A (es) 2019-08-21
WO2013126904A1 (en) 2013-08-29
EA032478B1 (ru) 2019-06-28
US20130224183A1 (en) 2013-08-29
MX2014010076A (es) 2014-09-22
HK1205520A1 (en) 2015-12-18
SI2817334T1 (sl) 2022-11-30
NZ628529A (en) 2016-09-30
AU2013203112B2 (en) 2016-03-10
AU2013203112A1 (en) 2013-09-12
EA201491564A1 (ru) 2015-04-30
JP6291423B2 (ja) 2018-03-14
CN104245730A (zh) 2014-12-24
US9782477B2 (en) 2017-10-10
KR20140135996A (ko) 2014-11-27
DK2817334T3 (da) 2022-10-03

Similar Documents

Publication Publication Date Title
KR101930582B1 (ko) 혈장으로부터 면역글로빈의 분획 i-iv-1 침전
JP6592120B2 (ja) 微細二酸化シリコンを用いた処理によるセリンプロテアーゼ除去法
TWI610937B (zh) 用於降低血漿來源免疫球蛋白組成物之血栓性栓塞可能性的方法
CN115397847A (zh) 由c-1抑制剂耗尽的血浆生产免疫球蛋白制剂的方法
HK40086420A (en) Fraction i-iv-1 precipitation of immunoglobins from plasma
HK1205520B (en) Fraction i-iv-1 precipitation of immunoglobins from plasma
AU2015293643A1 (en) Improved process for the preparation of immunoglobulin G (IgG)